维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

3篇 您的检索式：作者名="Natalia Ramirez"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Pharmacogenomics in colorectal cancer: The first step for individualized-therapy显示文摘Interindividual differences in the toxicity and response to anticancer therapies are currently observed in practically all available treatment regimens. A goal of cancer therapy is to predict patient response and toxicity to drugs in order to facilitate the individualization of patient treatment. Identification of subgroups of patients that differ in their prognosis and response to treatment could help to identify the best available drug therapy according the genetic profile. Several mechanisms have been suggested to contribute to chemo-therapeutic drug resistance: amplification or overexpression of membrane transporters, changes in cellular proteins involved in detoxification or in DNA repair, apoptosis and activation of oncogenes or tumor suppressor genes. Colorectal cancer (CRC) is regarded as intrinsically resistant to chemotherapy. Several molecular markers predictive of CRC therapy have been included during the last decade but their results in different studies complicate their application in practical clinical. The simultaneous testing of multiple markers predictive of response could help to identify more accurately the true role of these polymorphisms in CRC therapy. This review analyzes the role of genetic variants in genes involved in the action mechanisms of the drugs used at present in colorectal cancer.	Eva Bandrés Ruth Zárate Natalia Ramirez Ana Abajo Nerea Bitarte Jesus García-Foncillas	2007	World Journal of Gastroenterology2007，13，44：	4
	2	Moving forward in colorectal cancer research, what proteomics has to tell显示文摘Colorectal cancer is the third most common cancer and is highly fatal. During the last several years, research has been primarily based on the study of expression profiles using microarray technology. But now, investigators are putting into practice proteomic analyses of cancer tissues and cells to identify new diagnostic or therapeutic biomarkers for this cancer. Because the proteome reflects the state of a cell, tissue or organism more accurately, much is expected from proteomics to yield better tumor markers for disease diagnosis and therapy monitoring. This review summarizes the most relevant applications of proteomics the biomarker discovery for colorectal cancer.	Nerea Bitarte Eva Bandrés Ruth Zárate Natalia Ramirez Jesus Garcia-Foncillas	2007	World Journal of Gastroenterology2007，13，44：	3
	3	Cancer in inflammatory bowel disease 15<ce:hsp sp='0.25'/>years after diagnosis in a population-based European Collaborative follow-up study显示文摘	Konstantinos H. Katsanos Athina Tatsioni Natalia Pedersen Mary Shuhaibar Vicent Hernandez Ramirez Patrizia Politi Evelien Rombrechts Marieke Pierik Juan Clofent Marina Beltrami Paolo Bodini Joao Freitas Ioannis Mouzas Giovanni Fornaciari Bjorn Moum Peter	2011	Journal of Crohn’s and Colitis2011，，5：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费